SP 20102Alternative Names: SP20102
Latest Information Update: 05 Dec 2015
At a glance
- Originator Sarfez Pharmaceuticals
- Class Antifibrotics; Cardiovascular therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Fibrosis
Most Recent Events
- 05 Dec 2015 Phase-I clinical trials in Fibrosis in USA (unspecified route) prior to December 2015